Association for Human Pharmacology in the Pharmaceutical Industry Christmas Lecture

Event Date:
15 December 2020, 14:00 – 16:30 (GMT)
Location:
Virtual Meeting
View ProgramView Program

The Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI) is a membership organisation for professionals working within early drug development. The annual Christmas Lectures provide an opportunity for members to learn from industry experts and peers.

This year’s lectures will include a presentation by Richmond Pharmacology’s CEO and Founder, Jorg Taubel M.D.

Throughout 2020, Richmond Pharmacology quickly adapted recruitment and operational processes to safeguard research participants, staff and visitors to the London-based clinical research unit. Dr Taubel will share the new operating model for the COVID-secure facility and share lessons learned during this process.  

To attend the Christmas Lectures, please register here: https://cconline.eventsair.com/ahppi/ahppi2020/Site/Register

A summary of discussions of the 2019 annual meeting, which focused on impending change, innovation and future challenges, has been published. Read more in Frontiers in Pharmacology.


Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021
Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 
Read more

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

June 29, 2021
J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.
Read more

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

June 29, 2021
Data produced through Intellia Therapeutic’s NTLA-2001 FIH clinical trial, conducted at Richmond Pharmacology, indicates a reduction in the faulty TTR protein after a single infusion. Results were presented by Professor Julian Gillmore at this year’s Peripheral Nerve Society Annual Meeting.
Read more